Y90-Radioembolization and Nivolumab Therapy for Hepatocellular Carcinoma
Investigators assessed the activity and safety of Y90-radioembolization followed by nivolumab in patients with advanced hepatocellular carcinoma.
Hepatic Neoplasia
HEPATIC NEOPLASIA
Latest Articles
Patients With HCC Who Receive TACE Have Improved Survival
Investigators assessed long term outcomes of treatment with radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma.
Rivoceranib Designated Orphan Drug for Hepatocellular Carcinoma
Rivoceranib is an orally administered, small molecule inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2).
Higher Serum Iron May Increase Liver Cancer Risk in NAFLD Patients
Elevated serum iron and transferrin saturation levels are significantly associated with an increased risk for developing liver cancer in patients with NAFLD.
Weight Loss Medications May Reduce Risk for Cirrhosis and HCC
Investigators aimed to determine the potential correlation between weight loss medications and the development of cirrhosis and HCC among individuals with obesity.
Infigratinib Shows Meaningful Clinical Activity for Chemotherapy-Refractory Cholangiocarcinoma With FGFR2 Fusions or Rearrangements
Investigators evaluated the antitumor activity of infigratinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma and FGFR2 alterations.
LDLT Is an Independent Protective Factor of Reduced Mortality in Patients With HCC
Investigators assessed the benefit of a potential living donor on survival in patients with hepatocellular carcinoma on a waiting list for a liver transplant.
Meta-Analysis and Evidence Based Management of HCC
Investigators analyzed the current evidence for treatment of hepatocellular carcinoma and what factors might impact response to therapies.
Prevalence of Cardiac-Specific Mortality in Major GI Cancers
Investigators assessed the cardiac-specific mortality rate among patients with major GI cancers, as well as the relationship between radiation and chemotherapy with survival outcomes.
Lenvatinib Beneficial for Health-Related Quality of Life in Unresectable HCC
In a post-hoc analysis, researchers assessed the effects of lenvatinib compared with sorafenib on health-related quality of life in patients with hepatocellular carcinoma.
Statin Use Linked to Reduced Incident Cancer Risk in Heart Failure
Statin use was linked to a lower risk for incident cancer and cancer-related mortality in heart failure.
Statistical Model With AFP-R Better Predicts Success of Liver Transplant in Patients With HCC Recurrence
Researchers aimed to validate use of the NCYA score and its incorporation of AFP-R in the selection of patients for liver transplant due to HCC recurrence.
Atezolizumab Plus Bevacizumab Not Cost-Effective as First-Line Therapy for Unresectable or Metastatic HCC
Researchers compared the cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib for patients with unresectable or metastatic hepatocellular carcinoma.
Current Options for the Diagnosis and Treatment of Pediatric Patients With Liver Tumors
While pediatric liver tumors remain rare, their diagnosis and treatment requires a systematic approach from a multi-professional team of clinicians.
HCC: Does Exposure to DAAs Affect Recurrence Risk
Investigators conducted an international, multicenter meta-analysis to assess HCC recurrence risk in patients treated with DAAs.
Radioembolization Technology TheraSphere Approved for Hepatocellular Carcinoma
The approval was based on data from the LEGACY study, a single-arm, retrospective trial that evaluated treatment with TheraSphere Y90 glass microspheres in 162 patients with unresectable hepatocellular carcinoma.
HCC Surveillance in Patients With Cirrhosis
There is a need for interventions to increase HCC surveillance in patients with cirrhosis due to a high proportion of late-stage detection.
Zanidatamab Active in HER2-Positive Biliary Tract Cancer
Bernstam et al presented findings from an expansion cohort of a phase 1 trial testing the bispecific HER2-targeted antibody zanidatamab in patients with HER2-overexpressing biliary tract cancer.
Biomarkers for Liver Damage May Identify Early Liver Toxicity
A team of researchers created a machine learning system to identify liver toxicity related to chemical compounds used in a rat model.
Viral Exposure Signature Predicts Hepatocellular Carcinoma
A viral exposure signature can predict hepatocellular carcinoma (HCC) risk before clinical diagnosis among at-risk patients.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...